|
1) Margolin SB, Lefkowitz S. Pirfenidone: A novel pharmacologic agent for prevention and resolution of lung fibrosis. FASEB J. 1994; 8: A382
|
|
|
|
|
2) Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995; 125: 779-85
|
|
|
|
|
3) Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999; 291: 367-73
|
|
|
|
|
|
4) Tada S, Nakamuta M, Enjoji M, et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol. 2001; 28: 522-7
|
|
|
|
|
5) Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis int the post-obstructed kidney. Kidney Int. 1998; 54: 99-109
|
|
|
|
|
|
6) Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276: L311-8
|
|
|
|
|
|
7) Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomysin-induced pulmonary fibrosis. Eur Respir J. 2004; 24: 57-65
|
|
|
|
|
|
8) Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002; 446: 167-76
|
|
|
|
|
|
9) Piguet PF, Collart MA, Grau GE, et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989; 170: 655-63
|
|
|
|
|
|
10) 塩野義製薬(株)社内資料. ピルフェニドンの培養細胞を用いたin vitro試験
|
|
|
|
|
|
11) Mitani Y, Sato K, Muramoto Y, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun. 2008; 372: 19-23
|
|
|
|
|
|
12) 奥 久司. 7. 新規薬剤ピルフェニドン, 1)ピルフェニドンの作用機序について. 医薬ジャーナル. 2009; 45: 120-5
|
|
|
|
|
13) Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med. 1999; 159: 1061-9
|
|
|
|
|
|
14) Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040-7
|
|
|
|
|
|
15) Taniguch H, Ebina M, Knodoh Y, et al. and Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan. Eur Respir J. 2009. (in press)
|
|
|
|
|
|
16) InterMune社 press release (http://phx.corporate-ir.net/phoenix. zhtml？c＝100067&p＝irol-newsArticle&ID＝1251163&highlight＝)
|
|
|
|
|
|
17) Noble PW, Albera C, Bradford W, et al. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: Results of two randomized, double-blind, placebo controlled. Phase III trials (The CAPACITY Trials). ATS 2009, May15-20, San Diego, CA
|
|
|
|
|